Literature DB >> 32897133

Structural, Dosing, and Risk Change Factors Affecting Discontinuation of Pre-exposure Prophylaxis (PrEP) in a Large Urban Clinic.

Chelsea L Shover1,2, Michelle A DeVost1,3, Nicole J Cunningham1, Matthew R Beymer1, David Flores1, Risa Flynn1, Pamina M Gorbach1,4, Phoebe Lyman1, K Rivet Amico1,5, Robert K Bolan1.   

Abstract

Understanding why clients stop taking pre-exposure prophylaxis (PrEP) is critical to improve PrEP delivery and ultimately reduce HIV incidence. We analyzed data from a programmatic evaluation conducted at the Los Angeles LGBT Center from February to May 2018. Of 180 respondents to the emailed survey, 91 had stopped taking PrEP and 11 never started. Among former PrEP users, most common reasons for stopping were entering a monogamous relationship (43%) and side effects (40%). Ten of 11 who never started PrEP reported access barriers (e.g., cost, insurance problems). A quarter of inactive clients re-engaged with PrEP services following the survey and 15% restarted PrEP by October 2018. Improving PrEP retention may require multifaceted interventions-e.g., tailored discussions about stopping and restarting PrEP safely as HIV risk changes, ensuring consistent access to affordable PrEP, and alternative dosing strategies. An emailed survey may be a simple, effective strategy to reengage some PrEP clients.

Entities:  

Keywords:  HIV; pre-exposure prophylaxis; prevention; programmatic evaluation

Mesh:

Substances:

Year:  2020        PMID: 32897133      PMCID: PMC7886279          DOI: 10.1521/aeap.2020.32.4.271

Source DB:  PubMed          Journal:  AIDS Educ Prev        ISSN: 0899-9546


  18 in total

1.  Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic.

Authors:  Oni J Blackstock; Viraj V Patel; Uriel Felsen; Connie Park; Sachin Jain
Journal:  AIDS Care       Date:  2017-02-01

2.  Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.

Authors:  Julia L Marcus; Leo B Hurley; Charles Bradley Hare; Dong Phuong Nguyen; Tony Phengrasamy; Michael J Silverberg; Juliet E Stoltey; Jonathan E Volk
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-15       Impact factor: 3.731

3.  Preexposure Prophylaxis Initiation and Retention in Care Over 5 Years, 2012-2017: Are Quarterly Visits Too Much?

Authors:  Laura K Rusie; Carlos Orengo; Diane Burrell; Arthi Ramachandran; Magda Houlberg; Kristin Keglovitz; David Munar; John A Schneider
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

4.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.

Authors:  Sybil G Hosek; Raphael J Landovitz; Bill Kapogiannis; George K Siberry; Bret Rudy; Brandy Rutledge; Nancy Liu; D Robert Harris; Kathleen Mulligan; Gregory Zimet; Kenneth H Mayer; Peter Anderson; Jennifer J Kiser; Michelle Lally; Jennifer Brothers; Kelly Bojan; Jim Rooney; Craig M Wilson
Journal:  JAMA Pediatr       Date:  2017-11-01       Impact factor: 16.193

5.  High Rate of Discontinuation May Diminish PrEP Coverage Among Young Men Who Have Sex with Men.

Authors:  Ethan Morgan; Daniel T Ryan; Michael E Newcomb; Brian Mustanski
Journal:  AIDS Behav       Date:  2018-11

6.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

7.  Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM).

Authors:  Steven A Elsesser; Catherine E Oldenburg; Katie B Biello; Matthew J Mimiaga; Steven A Safren; James E Egan; David S Novak; Douglas S Krakower; Ron Stall; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2016-07

Review 8.  Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.

Authors:  K Rivet Amico; Leila E Mansoor; Amy Corneli; Kristine Torjesen; Ariane van der Straten
Journal:  AIDS Behav       Date:  2013-07

9.  Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi.

Authors:  Trisha Arnold; Lauren Brinkley-Rubinstein; Philip A Chan; Amaya Perez-Brumer; Estefany S Bologna; Laura Beauchamps; Kendra Johnson; Leandro Mena; Amy Nunn
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

10.  Defining the HIV pre-exposure prophylaxis care continuum.

Authors:  Amy S Nunn; Lauren Brinkley-Rubinstein; Catherine E Oldenburg; Kenneth H Mayer; Matthew Mimiaga; Rupa Patel; Philip A Chan
Journal:  AIDS       Date:  2017-03-13       Impact factor: 4.177

View more
  1 in total

1.  Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence.

Authors:  Maria Pyra; Russell Brewer; Laura Rusie; Jeanelle Kline; India Willis; John Schneider
Journal:  J Acquir Immune Defic Syndr       Date:  2022-02-01       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.